why is tirzepatide not fda approved Tirzepatide, the new medication for weight loss? The Impact of New FDA

Plant-based proteins like peas, beans, lentils, and hemp seeds provide amino acids while being gentle on digestion

The savings card program is valid for up to 48 months and includes maximum savings of $100 for a 28-day supply, $200 for a 56-day supply, and $300 for an 84-day supply

Track your progress through energy levels and how your clothes fit rather than relying solely on the scale

Approval Timeline and Availability CagriSema: Ahead in the Race FDA Submission: December 18, 2025 (NDA filed) Expected FDA Decision: Q4 2026 or Q1 2027 Predicted Launch: Mid-2027 Advantage: 6-12 month head start on retatrutide REDEFINE Program Status: REDEFINE-1: Completed (obesity, 20.4% weight loss) REDEFINE-2: Completed (type 2 diabetes, 13.7% weight loss) REDEFINE-3: Ongoing (cardiovascular outcomes trial) REDEFINE-8: Ongoing (body composition study) High-dose CagriSema (2.4/7.2mg): Starting late 2026 Retatrutide: More Trials Needed FDA Submission: Expected Q4 2026 or Q1 2027 Expected FDA Decision: Late 2027 Predicted Launch: Q1-Q2 2028 TRIUMPH Program Status: TRIUMPH-4: Completed (osteoarthritis, 28.7% weight loss) TRIUMPH-1: Complete 28.3% weight loss (May 2026) TRIUMPH-2: Expected Q3Q4 2026 (obesity + type 2 diabetes) TRIUMPH-3: Expected later 2026 (obesity + cardiovascular disease) TRIUMPH-6: Weight maintenance trial (ongoing) Disadvantage: Needs more trials before submission, 6-12 month delay vs CagriSema

Vitamins and minerals Certain nutrients, such as B vitamins, vitamins C and E, selenium, alpha-lipoic acid, and compounds found in cruciferous vegetables, play a key role in reducing oxidative stress and supporting the production and regeneration of glutathione

J., Syme, C